| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10885933 | Drug Discovery Today | 2014 | 5 Pages |
Abstract
- Specifically silencing mHTT can be accomplished by antisense oligonucleotides.
- Successes in stem cells and NPC studies move cell-based therapy forward.
- GET-NPT takes advantage of gene therapy in patient-derived cells for cell therapy.
- Noninvasively monitoring the transplanted cells in vivo is crucial.
- A transgenic HD monkey model is a suitable candidate for preclinical studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Yiju Chen, Richard L. Carter, In K. Cho, Anthony W.S. Chan,